Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Marketing Approval Deadline for RTW Purchase and Sale Agreement extended to June 30, 2027, buying more time for regulatory milestone.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Marketing Approval Deadline for RTW Purchase and Sale Agreement extended to June 30, 2027, buying more time for regulatory milestone
- RTW receives warrant for 375,000 shares at $4.00/share, expiring March 3, 2029: dilution cost for the extension
- RTW-affiliated funds committed to purchase minimum $5M of common stock within 90 days: near-term demand support for AQST shares
- Stock purchases priced under Rule 415(a)(4) (at-the-market pricing), limiting any premium benefit to existing shareholders
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year fiscal 2025 earnings reported; period ended December 31, 2025
- Full financial details and schedules in Exhibit 99.1 of this 8-K filing
Item 7.01 · Regulation FD Disclosure
- Aquestive (AQST) releasing updated investor presentation to institutional investors and analysts: potential catalyst for institutional interest
- Presentation filed as Exhibit 99.2; full content of disclosed information resides there
- Reg FD disclosure ensures retail investors receive simultaneous access to same information shared in private meetings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.